Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.67Last Year’s EPS
-0.55Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 05, 2025
|% Change Since: -0.33%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and a strong financial position, which were tempered by a decrease in revenue and increased operating expenses leading to a greater net loss. The advancements in clinical trials and robust financial backing are promising, yet the financial performance indicates some challenges.Company Guidance
During the EyePoint Fourth Quarter and Full Year 2024 Financial Results call, the company shared several key metrics and guidance for future developments. EyePoint reported a strong financial standing with $371 million in cash and investments and no debt, bolstered by a $161 million equity offering in Q4. The company's net revenue for Q4 2024 was $11.6 million, slightly down from $14 million in the previous year, primarily due to lower deferred revenue recognition. Operating expenses rose to $56.8 million, driven by ongoing Phase 3 trials for DURAVYU. The company is progressing its DURAVYU program in wet AMD with enrollment exceeding expectations, anticipating completion in the second half of 2025 and top-line data by 2026. EyePoint plans to hold an end of Phase 2 meeting with the FDA regarding the pivotal trial design for DURAVYU in DME. The focus remains on executing Phase 3 trials efficiently, with no immediate plans to access equity markets for additional funding.Advancement and Positive Results in Clinical Trials
EyePoint advanced DURAVYU into Phase 3 clinical trials for wet AMD and reported positive 24-week Phase 2 results in Diabetic Macular Edema (DME), with strong data supporting the potential for pivotal trials.
Strong Enrollment in Phase 3 Trials
Both Phase 3 trials for wet AMD, LUGANO and LUCIA, have surpassed enrollment expectations, with LUGANO well over 50% enrolled. Enrollment completion is expected in the second half of 2025.
Solid Financial Position
EyePoint ended 2024 with $371 million in cash and investments and no debt, bolstered by a $161 million oversubscribed equity offering.
Positive Phase 2 VERONA Clinical Trial Results
DURAVYU met primary and key secondary endpoints in the Phase 2 VERONA trial for DME, showing significant improvement in best corrected visual acuity and central subfield thickness compared to control.
---
EYPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EYPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 05, 2025 | $6.08 | $6.58 | +8.22% |
| Nov 07, 2024 | $12.08 | $11.59 | -4.06% |
| Aug 07, 2024 | $9.02 | $8.65 | -4.10% |
| May 08, 2024 | $11.87 | $11.56 | -2.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does EyePoint Pharmaceuticals Inc (EYPT) report earnings?
EyePoint Pharmaceuticals Inc (EYPT) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is EyePoint Pharmaceuticals Inc (EYPT) earnings time?
EyePoint Pharmaceuticals Inc (EYPT) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EYPT EPS forecast?
EYPT EPS forecast for the fiscal quarter 2025 (Q1) is -0.67.
---